BofA analyst Geoff Meacham downgraded Lyell Immunopharma (LYEL) to Underperform from Buy with a price target of $1, down from $6.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL: